Document Detail


A system mathematical model of a cell-cell communication network in amyotrophic lateral sclerosis.
MedLine Citation:
PMID:  23287963     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Amyotrophic lateral sclerosis (ALS) is a devastating and chronic neurodegenerative disease without any known cure. In the brain and spinal cord of both patients and animal models with ALS, neuroinflammation is a prominent pathological hallmark which is characterized by infiltrating T cells at sites of motor neuron injury. Their presence in mutant Cu(2+)/Zn(2+) superoxide dismutase (mSOD1) induced ALS plays an important role in shifting the response of microglia from neuroprotective to neurotoxic. In order to better understand how these cells and their communication network collectively modulate the disease progression, we have established a mathematical model integrating diverse cells and cytokines. According to the experimental data sets, we first refined this model by identifying a link between TGFβ and M1 microglia which can produce an optimized model to fit data sets better. Then based on this model, parameters were estimated using genetic algorithm. Sensitivity analysis of these parameters identified several factors such as the release rate of IFNγ by T helper 1 (Th1) cells, which may be related to the heterogeneity between the patients with different survival times. Furthermore, the tests on T cell based therapeutic strategies indicated that elimination of Th1 cells is the most effective approach extending survival time. This confirmed the dominant role of Th1 cells in leading the rapid disorder in the later stage of ALS. For the therapies targeting cytokines, injection of IL6 can essentially augment the neuroprotective response and extend the life effectively by elevating the level of IL4, a neuroprotective cytokine, while directly injected IL4 will decay rapidly in the ALS microenvironment and cannot provide a persistent protective effect. On the other hand, in spite of the attractive effect of direct elimination of mSOD1 or self-antigen, it is difficult to implement in CNS. As an alternative, elimination of IFNγ can be chosen as another effective therapy. In the future, if we combine the side effects of different therapies, this model can be used to optimize the therapeutic strategies so that they can effectively improve survival rates and quality of life for patients with ALS.
Authors:
Hongwei Shao; Ying He; King C P Li; Xiaobo Zhou
Related Documents :
24997483 - Quantitative indices of autophagy activity from minimal models.
22889343 - A tutorial review of electrical neuroimaging from group-average to single-trial event-r...
16881393 - The ecology of the parasite population in micro-mammals in the italian peninsula and is...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-01-04
Journal Detail:
Title:  Molecular bioSystems     Volume:  9     ISSN:  1742-2051     ISO Abbreviation:  Mol Biosyst     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-05     Completed Date:  2013-07-17     Revised Date:  2014-03-07    
Medline Journal Info:
Nlm Unique ID:  101251620     Medline TA:  Mol Biosyst     Country:  England    
Other Details:
Languages:  eng     Pagination:  398-406     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms
Amyotrophic Lateral Sclerosis / drug therapy,  enzymology,  immunology,  pathology*
Animals
Cell Communication*
Computer Simulation*
Cytokines / pharmacology,  physiology
Humans
Metabolic Networks and Pathways
Mice
Microglia / drug effects,  pathology
Models, Biological*
Motor Neurons / drug effects,  pathology
Superoxide Dismutase / genetics
T-Lymphocytes, Regulatory / immunology
Th2 Cells / immunology
Grant Support
ID/Acronym/Agency:
1R01DE022676-01/DE/NIDCR NIH HHS; R01 DE022676/DE/NIDCR NIH HHS; R01 LM010185/LM/NLM NIH HHS; R01LM010185-03/LM/NLM NIH HHS; U01 HL111560/HL/NHLBI NIH HHS; U01HL111560-01/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cytokines; EC 1.15.1.-/superoxide dismutase 1; EC 1.15.1.1/Superoxide Dismutase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is the assessment of the central skeleton sufficient for osseous staging in breast cancer patients? ...
Next Document:  Diffusion imaging-based subdivision of the human hypothalamus: a magnetic resonance study with clini...